Kinase Therapeutic Pipelines: An Assessment of Targets and Agents in Development
By Peter Norman, PhD, MBA
FIGURES
Figure 1.1. The Human Kinome
Figure 3.1. Mitogen-Activated Protein Kinase Signaling Cascades
Figure 4.1. Selectivity Profiles of Staurosporine and 3 Marketed Protein Kinase Inhibitors
Figure 4.2. Genetic SWOT Analysis for Kinase Inhibitors
Figure 5.1. Leading Oncology Franchises in 2006 and Proportion of Revenues Derived from Kinase Inhibitors and Growth Factor Receptor Antibodies
Figure 5.2. Kinase Inhibitors in Development from the Major Pharmaceutical Companies
TABLES
Table 1.1. AGC Family of Protein Kinases, Listed in Order of Phylogenetic Similarity
Table 1.2. CAMK Family of Protein Kinases, Listed in Order of Phylogenetic Similarity
Table 1.3. CMGC Family of Protein Kinases, Listed in Order of Phylogenetic Similarity
Table 1.4. CK1 Family of Protein Kinases, Listed in Order of Phylogenetic Similarity
Table 1.5. STE Family of Protein Kinases, Listed in Order of Phylogenetic Similarity
Table 1.6. TK Family of Protein Kinases, Listed in Order of Phylogenetic Similarity
Table 1.7. TKL Family of Protein Kinases, Listed in Order of Phylogenetic Similarity
Table 1.8. Families of Atypical Protein Kinases
Table 2.1. 2005 and 2006 Sales of Marketed Kinase Inhibitors
Table 2.2. 2005 and 2006 Sales of Marketed Recombinant Products
Table 5.1. Recently Approved Drugs Targeting Protein Kinases
Table 5.2. Kinase Inhibitors in Phase III Studies
Table 5.3. p38 MAP Kinase Inhibitors in Clinical Development
Table 5.4. MEK Inhibitors in Clinical Development
Table 5.5. PI3K Inhibitors in Clinical Development
Table 5.6. Akt Inhibitors in Clinical Development
Table 5.7. Cell Cycle (CDK and Chk) Inhibitors in Clinical Development
Table 5.8. Abl Inhibitors in Clinical Development
Table 5.9. Anti-angiogenic Kinase Inhibitors in Clinical Development
Table 5.10. IGFR Inhibitors in Clinical Development
Table 5.11. EGFR and ErbB2 Inhibitors in Clinical Development
Table 5.12. Flt3 Inhibitors in Clinical Development
Table 5.13. Inhibitors of Other Kinases in Phase II Clinical Development
Table 5.14. Aurora Kinase Inhibitors in Phase I Studies
Table 5.15. Raf Kinase Inhibitors in Phase I Studies
Table 5.16. Pan-FGF Inhibitors in Phase I Clinical Development
Table 5.17. Other Kinase Inhibitors in Phase I Studies